» Articles » PMID: 17432925

Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in the Elderly : an Appraisal of Published Evidence

Overview
Journal Drugs Aging
Specialties Geriatrics
Pharmacology
Date 2007 Apr 17
PMID 17432925
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic obstructive pulmonary disease (COPD) is a debilitating disease with rising worldwide prevalence. Exacerbations of COPD cause significant morbidity and become more common with advancing age. Healthcare providers caring for elderly patients should therefore be familiar with effective treatments for exacerbations of COPD. An extensive body of literature has identified several effective drug therapies for exacerbations. These drugs include inhaled bronchodilators, systemic corticosteroids and antibacterials. The two main classes of inhaled bronchodilators are beta-adrenoceptor agonists and anticholinergics. These drugs optimise lung function during exacerbations, with neither class demonstrating clear superiority over the other. Systemic corticosteroids are effective when used either for inpatient or outpatient treatment of exacerbations. They hasten recovery from exacerbations and reduce relapse rates. Antibacterials decrease morbidity from exacerbations and may decrease mortality in the more severe exacerbations. Other effective therapies for the treatment of acute exacerbations of COPD include oxygen and non-invasive ventilation. Oxygen can be safely administered in acute exacerbations associated with hypoxaemia, with titration of oxygen delivery to a goal oxygen saturation of 90%. Non-invasive ventilation reduces the morbidity and mortality associated with acute exacerbations complicated by hypercapnic respiratory failure. Strategies to prevent COPD exacerbations include smoking cessation, long-acting inhaled beta-adrenoceptor agonists, inhaled long-acting anticholinergics, inhaled corticosteroids and vaccination. Mucolytic agents, pulmonary rehabilitation, and case management programmes may also reduce exacerbation risk, but the current evidence supporting these interventions is weaker.

Citing Articles

Cardiopulmonary Rehabilitation in Elderly Patients with Heart Failure: A Prospective Cohort Study.

Zhou H, Dong A, Xu X, Zhu J, Shi B J Healthc Eng. 2022; 2022:4923007.

PMID: 35399850 PMC: 8993543. DOI: 10.1155/2022/4923007.


Eight-step method to build the clinical content of an evidence-based care pathway: the case for COPD exacerbation.

Lodewijckx C, Decramer M, Sermeus W, Panella M, Deneckere S, Vanhaecht K Trials. 2012; 13:229.

PMID: 23190552 PMC: 3543249. DOI: 10.1186/1745-6215-13-229.


The precarious balance between 'supply' and 'demand' for health care: the increasing global demand for rehabilitation service for individuals living with chronic obstructive pulmonary disease.

Landry M, Hamdan E, Al Mazeedi S, Brooks D Int J Chron Obstruct Pulmon Dis. 2008; 3(3):393-6.

PMID: 18990966 PMC: 2629990. DOI: 10.2147/copd.s3568.


What defines abnormal lung function in older adults with chronic obstructive pulmonary disease?.

Bhatt N, Wood K Drugs Aging. 2008; 25(9):717-28.

PMID: 18729545 DOI: 10.2165/00002512-200825090-00001.

References
1.
Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J . Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995; 152(4 Pt 1):1316-20. DOI: 10.1164/ajrccm.152.4.7551388. View

2.
West R, McNeill A, Raw M . Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000; 55(12):987-99. PMC: 1745657. DOI: 10.1136/thorax.55.12.987. View

3.
Foglio K, Bianchi L, Ambrosino N . Is it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airway obstruction? A 2-year controlled study. Chest. 2001; 119(6):1696-704. DOI: 10.1378/chest.119.6.1696. View

4.
Zhou R, Chen P, Luo H, Xiang X . [Effects of noninvasive positive pressure ventilation on gas exchange and patients' transformation in chronic obstructive pulmonary disease and respiratory failure]. Hunan Yi Ke Da Xue Xue Bao. 2003; 26(3):261-2. View

5.
Burge P, Calverley P, Jones P, Spencer S, ANDERSON J, Maslen T . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000; 320(7245):1297-303. PMC: 27372. DOI: 10.1136/bmj.320.7245.1297. View